Abstract:Mitochondrial dysregulation is closely associated with excessive reactive oxygen species (ROS) production. Altered redox homeostasis has been implicated in the onset of several diseases including cancer. Mitochondrial DNA (mtDNA) and proteins are particularly sensitive to ROS as they are in close proximity to the respiratory chain (RC). Mitoquinone (MitoQ), a mitochondria-targeted redox agent, selectively damages breast cancer cells possibly through damage induced via enhanced ROS production. However, the effects of MitoQ and other triphenylphosphonium (TPP+) conjugated agents on cancer mitochondrial homeostasis remain unknown. The primary objective of this study was to determine the impact of mitochondria-targeted agent [(MTAs) conjugated to TPP+: mitoTEMPOL, mitoquinone and mitochromanol-acetate] on mitochondrial physiology and mtDNA integrity in breast (MDA-MB-231) and lung (H23) cancer cells. The integrity of the mtDNA was assessed by quantifying the degree of mtDNA fragmentation and copy number, as well as by measuring mitochondrial proteins essential to mtDNA stability and maintenance (TFAM, SSBP1, TWINKLE, POLG and POLRMT). Mitochondrial status was evaluated by measuring superoxide production, mitochondrial membrane depolarization, oxygen consumption, extracellular acidification and mRNA or protein levels of the RC complexes along with TCA cycle activity. In this study, we demonstrated that all investigated MTAs impair mitochondrial health and decrease mtDNA integrity in MDA-MB-231 and H23 cells. However, differences in the degree of mitochondrial damage and mtDNA degradation suggest unique properties among each MTA that may be cell line, dose and time dependent. Collectively, our study indicates the potential for TPP+ conjugated molecules to impair breast and lung cancer cells by targeting mitochondrial homeostasis.

Targeting the nucleic acid oxidative damage repair enzyme MTH1: a promising therapeutic option

Role of MTH1 in oxidative stress and therapeutic targeting of cancer

Targeting Human MutT Homolog 1（MTH1） for Cancer Eradication:Current Progress and Perspectives

Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.

Targeted Gsh-Exhausting And Hydroxyl Radical Self-Producing Manganese-Silica Nanomissiles For Mri Guided Ferroptotic Cancer Therapy

MTH1 inhibition synergizes with ROS-inducing agents to trigger cervical cancer cells undergoing parthanatos

Investigation of MTH1 Activity Via Mismatch-Based DNA Chain Elongation.

Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer.

Augment of Oxidative Damage with Enhanced Photodynamic Process and MTH1 Inhibition for Tumor Therapy

Targeting the DNA repair enzymes MTH1 and OGG1 as a novel approach to treat inflammatory diseases.

Inhibitor development of MTH1 via high-throughput screening with fragment based library and MTH1 substrate binding cavity

Mitochondrial DNA is a sensitive surrogate and oxidative stress target in oral cancer cells

Mitochondria-Targeted Antioxidants: A Step towards Disease Treatment

Small molecule inhibitor of OGG1 blocks oxidative DNA damage repair at telomeres and potentiates methotrexate anticancer effects

The defense mechanisms in mammalian cells against oxidative damage in nucleic acids and their involvement in the suppression of mutagenesis and cell death

Potential application of the oxidative nucleic acid damage biomarkers in detection of diseases

Therapeutic targeting nudix hydrolase 1 creates a MYC-driven metabolic vulnerability

Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

Platinum-based nanocomposites loaded with MTH1 inhibitor amplify oxidative damage for cancer therapy

Therapeutic Targeting of the Mitochondria Initiates Excessive Superoxide Production and Mitochondrial Depolarization Causing Decreased mtDNA Integrity

OGG1: An emerging multifunctional therapeutic target for the treatment of diseases caused by oxidative DNA damage